References
- EMA. Stelara summary of product characteristics, Janssen-Cilag International NV, Belgium. [cited 12 May 2015]. https://www.ema.europa.eu/en/medicines/human/EPAR/stelara#product
- Pharmaceuticals and Medical Devices Agency (PMDA). Report On The Deliberation Results. 17 Feb 2017; [cited 09 May 2023]. https://www.pmda.go.jp/files/000227668.pdf
- EPAR EMA. [cited 12 May 2015]. https://www.ema.europa.eu/en/documents/product-information/stelara-eparproduct-information_en.pdf
- FDA. Stelara US-Prescribing Information. [cited 12 May 2015]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125261s150lbl.pdf
- Xian, Janssen. Stelara Chinese product information. [cited 12 May 2015]. https://www.xian_janssen.com.cn/sites/default/files/PDF/13fu_jian_wu_si_nu_dan_kang_zhu_she_ye_shuo_ming_shu__20200311.pdf
- Chen BK, Yang YT, Bennett CL. Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the supreme court’s recent rulings do not solve fundamental barriers to competition. Drugs. 2018;78(17):1777–1781. doi: 10.1007/s40265-018-1009-0
- McCamish M, Yoon W, McKay J. Biosimilars: biologics that meet patients’ needs and healthcare economics. Am J Manag Care. 2016;22(13 Suppl):S439–42.
- European Medicines Agency. Guideline on similar biological medicinal products. [cited 3 Apr 2015]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- US Department of Health and Human Services. Biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Guidance for industry. [cited 22 May 2017]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. [cited 22 May 2017]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
- European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. [cited 6 Jan 2016]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf
- US Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance For Industry. [cited 12 May 2015]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
- Berti F, Wynne C, Stroissnig H, et al.; Assessment of bioequivalence between candidate biosimilar AVT04 and reference ustekinumab. Presented At: AAD 2023; Mar 17-21, 2023; [cited 25 Apr 2023]. https://eposters.aad.org/abstracts/42601
- Wynne C, Hamilton P, McLendon K, et al. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults. Expert Opin Investig Drugs. 2023 May;32(5):1–11.
- EMA. Guidance on the management of clinical trials during the COVID-19 (Corona Virus) pandemic. [cited 12 Aug 2021]. https://ec.europa.eu/health/sites/default/fles/fles/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005 Mar;64(Suppl 2):ii65–ii68. doi: 10.1136/ard.2004.031237
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216.
- van Voorhees A, Feldman SR, Koo JYM, et al. The psoriasis and psoriatic arthritis pocket guide. 4th edition. Alexandria, VA: National Psoriasis Foundation; 2016.
- Civoli F, Kasinath A, Cai XY, et al. Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. Aaps J. 2019 Dec;22(1):7.
- EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 01 Jul 2015. EMEA/CHMP/BMWP/42832/2005 Rev.1. [Accessed 3 Aug 2020]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biologicalmedicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
- EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 01/12/2014. CHMP/BWP/247713/2012. [cited 3 Aug 2020]. https://www.ema.europa.eu/en/documents/scientific-guideline/guidelinesimilar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en1.pdf
- EMA. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use 1 Dec 2012. EMA/CHMP/BMWP/86289/2010. [cited 03 Aug 2020]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicityassessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf
- FDA. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, final guidance Dec 2016. [cited 3 Aug 2020]. https://www.fda.gov/media/88622/download
- Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet. 2008 May 17;371(9625):1665–1674.
- Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet. 2008 May 17;371(9625):1675–1684.
- U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Considerations in demonstrating interchangeability with a reference product: guidance for industry. May 2019. [cited 9 May 2023]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry
- EMA. Assessment report for Stelara. stelara-epar-public-assessment-report_en.Pdf (europa.eu). [cited 9 May 2023]. https://www.ema.europa.eu/en/documents/assessment-report/stelara-epar-public-assessment-report_en.pdf